Individual Investors

Subscribe to email updates

Subscribe now

Financial Professionals

Subscribe to email updates, or password protected financial professional-only content
email address/username
password

GNRX
VanEck Vectors Generic Drugs ETF

  • Fund Description

    VanEck Vectors® Generic Drugs ETF (GNRX) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Indxx Global Generics & New Pharma Index (IGNRXT), which is intended to track the overall performance of companies that derive a significant proportion of their revenues or that have the potential to derive a significant proportion of their revenues from the generic drug industry, or that have a primary business focus on the generic drug industry.

  •  
      

    • Fund Ticker

      GNRX
    • Exchange

      NASDAQ
    • Commencement

      01/12/2016
    • ETF Structure

      Physical
    • Administrator

      Van Eck Associates
    • Custodian

      Bank of New York Mellon
    • Index Ticker

      IGNRXT
    • Index Rebalancing

      Semi-Annual
  •  
    as of 09/22/17

    • 30-Day SEC Yield1

      0.27%
    • Total Net Assets

      $3.4M
    • Number of Holdings

      41
    • Options

      Expected
    • Gross Expense Ratio2

      5.70%
    • Net Expense Ratio/TER2

      0.55%
    • Distribution Frequency

      Annual
    • Next Distribution Date

      12/15/17
  • Key Points

    Industry may benefit from ongoing push to lower health care costs


    The only ETF offering global exposure to generic drug producers


    Positioned to take advantage of the expected growth of biosimilars

     

  • Trading Information

    • Fund Ticker

      GNRX
    • Index Total Return Ticker

      IGNRXT
    • NAV

      GNRXNV
    • Intraday NAV (IIV)4

      GNRXIV
    • Shares Outstanding

      150,000
    • Estimated Cash

      GNRXEU
    • Total Cash

      GNRXTC
    • CUSIP

      92189F577
    • ISIN

      US92189F5778
    Source: Bloomberg
  • Fees and Expenses2

    • Management Fee

      0.50%
    • Other Expenses

      5.20%
    • Gross Expense Ratio

      5.70%
    • Fee Waivers and
      Expense Reimbursement

      -5.15%
    • Net Expense Ratio/TER2

      0.55%
    2 Expenses for GNRX are capped contractually at 0.55% until at least February 1, 2018. Cap excludes certain expenses, such as interest.
  • Prices as of 09/22/17

    NAV/
    Last Price
    Volume
    30-Day Avg./
    Last Trading Day
    Daily Change
    NAV/
    Last Price
    YTD Change
    NAV/
    Last Price
    Premium/
    Discount
    Prem/Discount
    Distribution Charts
    NAV &
    Prem/Discount
    History
    NAV
    Chart
    GNRX $22.52
    $22.39
    923
    701
    -$0.04 / -0.16%
    $0.00 / +0.00%
    +6.08%
    +4.29%
    $-0.13
    -0.56%
  • View All IndicesView All ETFsPerformance History: Average Annual Total Returns* (%)

    1 MO3 MOYTD1 YR3 YR5 YR10 YRLIFE
    01/12/16
    GNRX (NAV)-5.02-0.962.50-10.41-------8.35
    GNRX (Share Price)-5.54-0.641.63-10.68-------8.20
    IGNRXT (Index)-5.10-0.962.49-9.67-------7.64
    Performance Differential (NAV - Index)0.080.000.01-0.74-------0.71
    Quarter End as of 06/30/17
    1 MO3 MOYTD1 YR3 YR5 YR10 YRLIFE
    01/12/16
    GNRX (NAV)4.052.057.68-3.95-------6.17
    GNRX (Share Price)2.60-0.094.94-5.10-------7.09
    IGNRXT (Index)4.042.107.66-2.75-------5.35
    Performance Differential (NAV - Index)0.01-0.050.02-1.20-------0.82
  • Daily HoldingsTop 10 Holdings (%)  as of 08/31/17

    Total Holdings: 41
    Holding Name
    Ticker
    SharesMarket Value
    (US$)
    % of Net
    Assets
    Quintiles Ims Holdings Inc
    Q US
    2,531
    243,0527.45
    Lonza Group Ag
    LONN VX
    798
    201,8856.19
    Sun Pharmaceutical Industries Ltd
    SUNP IN
    25,588
    192,6395.90
    Mylan Nv
    MYL US
    5,367
    168,9535.18
    Ucb Sa
    UCB BB
    2,087
    143,8804.41
    Albemarle Corp
    ALB US
    1,207
    140,3264.30
    Celltrion Inc
    068270 KS
    1,313
    134,4464.12
    Teva Pharmaceutical Industries Ltd
    TEVA US
    8,045
    127,5943.91
    Perrigo Co Plc
    PRGO US
    1,538
    121,4403.72
    Aspen Pharmacare Holdings Ltd
    APN SJ
    4,897
    109,2773.35
    Top 10 Total (%)48.53
    These are not recommendations to buy or to sell any security. Securities and holdings may vary.
  • Country Weightings (%) as of 08/31/17

    • Country

      % of Net Assets
    • UNITED STATES

      31.07
    • INDIA

      21.50
    • CHINA

      8.26
    • JAPAN

      7.32
    • SWITZERLAND

      6.19
    • SOUTH KOREA

      5.75
    • BELGIUM

      4.41
    • ISRAEL

      3.91
    • SOUTH AFRICA

      3.35
    • INDONESIA

      1.98
    • GERMANY

      1.91
    • FINLAND

      1.60
    • HUNGARY

      1.59
    • JORDAN

      1.27
    • Other/Cash

      -0.11
  • Sector Weightings (%) as of 08/31/17

    • Sector

      % of Net Assets
    • Health Care

      95.8
    • Materials

      4.3
    • Other/Cash

      -0.1
  • Important Disclosure

    VanEck only serves professional clients in countries where the funds are registered or where funds can be sold in accordance with local private placement rules.

    130-Day SEC Yield is a standard yield calculation developed by the Securities and Exchange Commission that allows for fairer comparisons among funds. It is based on the most recent 30-day period. This yield figure reflects the interest earned during the period after deducting the fund's expenses for the period. It does not reflect the yield an investor would have received if they had held the fund over the last twelve months assuming the most recent Net Asset Value (NAV). Distributions may vary from time to time. In the absence of temporary expense waivers or reimbursements, the 30-Day SEC Yield for VanEck Vectors Generic Drugs ETF would have been -2.09% on 08/31/17.

    2Fees & Expenses for GNRX are capped contractually at 0.55% until at least 2/01/18. Cap excludes certain expenses, such as interest. TER, or Total Expense Ratio, is also referred to as "Net Expense Ratio".

    3Morningstar Ratings : If applicable, when the ETF is rated three stars or more for any given period. ©Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

    4IIV is an abbreviation for the intraday indicative value of an ETF's Shares (and is also known as the Indicative Optimized Portfolio Value or IOPV), and is disseminated every 15 seconds during regular trading hours. The IIV is based on the current market value of the securities and/or cash required to be deposited in exchange for a Creation Unit. The IIV does not necessarily reflect the precise composition of the current portfolio of securities held by the Fund at a particular point in time or the best possible valuation of the current portfolio. Therefore, the IIV should not be viewed as a "real-time" update of the Fund's NAV, which is computed only once a day. The Fund is not involved in, or responsible for, the calculation or dissemination of the IIV and makes no warranty as to its accuracy.

    6The S&P 500® Index consists of 500 widely held common stocks covering industrial, utility, financial and transportation sector; as an Index, it is unmanaged and is not a security in which investments can be made.

    Price/Book Ratio is the price of a security divided by the book value per share of the security. Price/Earnings Ratio is the price of a security divided by the earnings per share of the security.

    An investment in the Fund may be subject to risks which include, among others, investing in the pharmaceutical and biotechnology sectors, equity securities, special risk considerations of investing in Indian and Asian issuers, depositary receipts, foreign securities, emerging market issuers, foreign currency, small- and medium-capitalization companies, market, operational, index tracking, replication management, cash transactions, authorized participant concentration, no guarantee of active trading market, trading issues, fund shares trading, premium/discount risk and liquidity of fund shares, non-diversified, and concentration risks. Foreign and emerging markets investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, changes in currency exchange rates, unstable governments, and limited trading capacity which may make these investments volatile in price or difficult to trade. Small- and medium-capitalization companies may be subject to elevated risks. The Fund’s assets may be concentrated in a particular sector and may be subject to more risk than investments in a diverse group of sectors. 

    Indxx Global Generics & New Pharma Index (the "Index”) is the exclusive property of Indxx, LLC. Indxx, LLC uses its best efforts to ensure that the Index is calculated correctly. Indxx, LLC has no obligation to point out errors in the Index to third parties. VanEck Vectors Generic Drugs ETF is not sponsored, endorsed, sold or promoted by Indxx, LLC and Indxx, LLC makes no representation regarding the advisability of investing in VanEck Vectors Generic Drugs ETF.

    Index returns are not Fund returns and do not reflect any management fees or brokerage expenses. Investors can not invest directly in the Index. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. Index returns assume that dividends have been reinvested.

    The NAV of a VanEck Vectors Exchange Traded Fund (ETF) is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF's intraday trading value. VanEck Vectors ETF investors should not expect to buy or sell shares at NAV.

    Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called "creation units" and otherwise can be bought and sold only through exchange trading. Shares may trade at a premium or discount to their NAV in the secondary market. You will incur brokerage expenses when trading Fund shares in the secondary market. Past performance is no guarantee of future results. Returns for actual Fund investments may differ from what is shown because of differences in timing, the amount invested, and fees and expenses.

    Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus , which contains this and other information, call 800.826.2333 or visit vaneck.com/etfs. Please read the prospectus and summary prospectus carefully before investing.

    This content is published in the United States for residents of specified countries. Investors are subject to securities and tax regulations within their applicable jurisdictions that are not addressed on this content. Nothing in this content should be considered a solicitation to buy or an offer to sell shares of any investment in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction, nor is it intended as investment, tax, financial, or legal advice. Investors should seek such professional advice for their particular situation and jurisdiction.